Collegium Pharmaceutical, Inc. COLL Segment — Stock-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense?
- Collegium Pharmaceutical, Inc. (COLL) reported segment — stock-based compensation expense of $10.88M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense changed year-over-year?
- Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense decreased by 5.6% year-over-year, from $11.52M to $10.88M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense has grown at a 22.4% compound annual growth rate (CAGR), from $22.87M to $41.91M.
- What does segment — stock-based compensation expense mean?
- Represents the non-cash expense recognized for equity-based awards granted to employees and executives as part of their compensation packages. This metric is used to evaluate the cost of talent retention and its impact on overall profitability.